识别梅尼埃病治疗反应预测因素:一种临床严重度分期系统
该回顾性队列研究纳入2016年1月1日至2019年12月31日新诊断的78例梅尼埃病成人患者,49例(63%)对保守治疗有反应,29例(37%)无反应。有反应者中无或轻度眩晕、无或轻度合并症比例更高,听力损失比例更低;基于这3个因素构建的三期分期系统治疗反应率分别为100%、64%、18%。
要点
- 新诊断梅尼埃病患者中63%对保守治疗有反应,37%无反应。
- 无或轻度眩晕、无或轻度合并症、无听力损失与保守治疗反应相关。
- 基于3因素的三期分期系统反应率分别为100%、64%、18%。
核心结论
- 眩晕严重度较低、合并症负担较轻及无听力损失是与梅尼埃病保守治疗反应相关的因素。
- 包含这3个因素的复合临床严重度分期系统可用于优化治疗选择并促进以患者为中心的管理。
研究设计与样本
- 回顾性队列研究,纳入2016年1月1日至2019年12月31日期间新诊断的梅尼埃病成人患者。
- 排除既往接受过梅尼埃病治疗、既往耳科手术或缺乏随访数据的患者。
- 治疗有反应者仅接受保守治疗(如饮食调整、利尿剂),无反应者接受更强化治疗(如鼓室内操作、手术干预)。
- 共纳入78例患者。
主要发现
- 78例患者中49例(63%)对保守治疗有反应,29例(37%)无反应。
- 有反应者中无或轻度眩晕的比例为24%(95%CI:3.1%-45.8%),高于无反应者。
- 有反应者中无或轻度合并症的比例为27%(95%CI:9.2%-44.7%),高于无反应者。
- 有反应者中听力损失的比例为19%(95%CI:5.6%-32.4%),低于无反应者。
- 对3个因素进行联合整合构建三期系统,1期(n=11)、2期(n=56)、3期(n=11)的治疗反应率分别为100%、64%、18%。
临床怎么用
- 作者认为,包含眩晕严重度、合并症负担及听力损失状态的复合临床严重度分期系统可用于优化梅尼埃病的治疗选择并促进以患者为中心的管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Identify clinically important factors associated with conservative treatment response in Meniere's disease and incorporate these factors into a composite clinical severity staging system. STUDY DESIGN: Retrospective cohort. SETTING: Tertiary academic medical center. METHODS: Adult patients newly diagnosed with Meniere's disease between January 1, 2016 and December 31, 2019 were eligible. Patients with previous treatment for Meniere's disease, prior otologic surgery, or a lack of follow-up data were excluded. Treatment-responsive patients were managed with only conservative therapies (eg, dietary modifications, diuretics) and unresponsive patients underwent more intensive therapies (eg, intratympanic procedures, surgical interventions). RESULTS: Of 78 patients included in the study, 49 (63%) were responsive to conservative therapies and 29 (37%) were not. Responsive patients had higher proportions of no or mild vertigo (24%, 95% confidence interval [CI]: 3.1%-45.8%) and none or mild comorbidity (27%, 95% CI: 9.2%-44.7%) and a lower proportion of hearing loss (19%, 95% CI: 5.6%-32.4%) compared to unresponsive patients. Conjunctive consolidation of these 3 factors was performed to develop a three-stage system with a treatment response gradient ranging from 100% to 64% to 18% for stage 1 (n = 11), stage 2 (n = 56), and stage 3 (n = 11), respectively. CONCLUSIONS: This study identified decreased vertigo severity, reduced comorbidity burden, and absence of hearing loss as factors associated with conservative treatment response in Meniere's disease. A composite clinical severity staging system including these 3 factors can be used to optimize treatment selection and promote patient-centered management of Meniere's disease.
引用
- Miller BJ, Kallogjeri D, Shew MA, et al. Identifying Predictors of Treatment Response in Meniere's Disease: A Clinical Severity Staging System. Otolaryngol Head Neck Surg. 2023. PMID: 37622528. doi:10.1002/ohn.486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。